- Home
- KALA vs GSIW Comparison
KALA vs GSIW Comparison
Compare KALA & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- GSIW
- Stock Information
- Founded
- KALA 2009
- GSIW 2016
- Country
- KALA United States
- GSIW Hong Kong
- Employees
- KALA N/A
- GSIW N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- GSIW
- Sector
- KALA Health Care
- GSIW
- Exchange
- KALA Nasdaq
- GSIW Nasdaq
- Market Cap
- KALA 26.2M
- GSIW 27.2M
- IPO Year
- KALA 2017
- GSIW 2023
- Fundamental
- Price
- KALA $5.60
- GSIW $1.63
- Analyst Decision
- KALA Strong Buy
- GSIW
- Analyst Count
- KALA 3
- GSIW 0
- Target Price
- KALA $14.00
- GSIW N/A
- AVG Volume (30 Days)
- KALA 125.3K
- GSIW 2.5M
- Earning Date
- KALA 08-05-2025
- GSIW 01-01-0001
- Dividend Yield
- KALA N/A
- GSIW N/A
- EPS Growth
- KALA N/A
- GSIW N/A
- EPS
- KALA N/A
- GSIW N/A
- Revenue
- KALA N/A
- GSIW $1,313,795.00
- Revenue This Year
- KALA N/A
- GSIW N/A
- Revenue Next Year
- KALA N/A
- GSIW N/A
- P/E Ratio
- KALA N/A
- GSIW N/A
- Revenue Growth
- KALA N/A
- GSIW N/A
- 52 Week Low
- KALA $2.92
- GSIW $0.35
- 52 Week High
- KALA $11.20
- GSIW $12.30
- Technical
- Relative Strength Index (RSI)
- KALA 59.32
- GSIW 71.78
- Support Level
- KALA $5.56
- GSIW $1.26
- Resistance Level
- KALA $7.00
- GSIW $1.65
- Average True Range (ATR)
- KALA 0.72
- GSIW 0.15
- MACD
- KALA 0.08
- GSIW -0.02
- Stochastic Oscillator
- KALA 59.00
- GSIW 90.25
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.